Gesundheit Österreich was commissioned by the Global AMR R&D Hub to conduct two “trans-national studies to inform national policy maker options in addressing novel antibiotic and diagnostic reimbursement and purchasing”. The studies aim to provide evidence on policy options for antibiotics and diagnostics in the field of Antimicrobial Resistance (AMR), which has become a complex issue of major global concern. In particular, the studies aim to identify and assess policy options which can incentivise producers to invest in the production of novel antibiotics and diagnostics and thus contribute to enhancing access and universal health coverage. The studies will look into areas of highest unmet need and focus on the pricing and reimbursement as well as on procurement mechanisms in ten selected countries across the globe.
Last update: 18 March 2020
